The usefulness of new serum tumor markers in head and neck squamous cell carcinoma

Otolaryngology - Head and Neck Surgery

Volumn 140, Issue 3, 2009, Pages 375-380

  Marcos, César Álvarez ^a,d   Martínez, Daniel Al Kassam ^a   de los Toyos, Juan Ramón ^a,b   Domínguez Iglesias, Francisco ^a   Hermsen, Mario ^a,c,d   Guervós, Marta Alonso ^a,c,d   Pendás, José Luis Llorente ^a,c,d  

^a HOSPITAL VALLE DEL NALÓN   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; COLLAGENASE 3; GELATINASE A; GELATINASE B; PROTEIN P53; TUMOR MARKER; UVOMORULIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CERVICAL LYMPH NODE; CONTROLLED STUDY; FEMALE; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; ROC CURVE; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

CADHERINS; CARCINOMA, SQUAMOUS CELL; CROSS-SECTIONAL STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 60549084884     PISSN: 01945998     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otohns.2008.12.026     Document Type: Article

References (20)

1. In: Barnes L., Eveson J.W., Reichart P., et al. (Eds). World Health Organization Classification of tumours. Pathology and genetics of head and neck tumours (2005), IARC Press, Lyon
2. Al Kassam D., Alvarez Marcos C., Blanco I., et al. Diagnostic value of E-cadherin, MMP-9, activated MMP-13 and anti-p53 antibodies in squamous cell carcinomas of head and neck. Med Clin (Barcelona) 129 (2007) 761-765
3. Mbalaviele G., Dustan C.R., Susaki A., et al. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastasis in an experimental metastasis model. Cancer Res 56 (1996) 4063-4070
4. Rodrigo Tapia J.P., Domínguez Iglesias F., Álvarez Marcos C.A., et al. Expresion of E-cadherin in squamous cell carcinomas of the supraglottic larynx with correlations to clinicopathological features. Eur J Cancer 38 (2002) 1059-1064
5. Charalabopoulos K., Gogali A., Dalavaga Y., et al. The clinical significance of soluble E-cadherin in nonsmall cell lung cancer. Exp Oncol 28 (2006) 83-85
6. De Wever O., Derycke L., Hendrix A., et al. Soluble cadherins as cancer biomarkers. Clin Exp Metastasis 24 (2007) 685-697
7. Puente X.S., Pendás A.M., Llano E., et al. Molecular cloning of a novel membrane-type matrix metalloproteinase from human breast carcinoma. Cancer Res 56 (1996) 944-949
8. Nikkola J., Vihinen P., Vuoristo M.S., et al. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 11 (2005) 5158-5166
9. Franchi A., Santucci M., Masini E., et al. Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer 95 (2002) 1902-1910
10. Cazorla M., Hernández L., Nadal A., et al. Collagenase-3 expresion is associated with advanced local invasion in human squamous cell carcinomas of the larynx. J Pathol 186 (1998) 144-150
11. Vairaktaris E., Yapijakis C., Nkenke E., et al. A metalloproteinase-13 polymorphism affecting its gene expression is associated with advanced stages of oral cancer. Anticancer Res 27 (2007) 4027-4030
12. Luukkaa M., Vihinen P., Kronqvist P., et al. Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer. Head Neck 28 (2006) 225-234
13. Müller M., Meyer M., Schilling T., et al. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. Int J Oncol 29 (2006) 973-980
14. Mattioni M., Soddu S., Porrello A., et al. Serum anti-p53 antibodies as a useful marker for prognosis of gastric carcinoma. Int J Biol Markers 22 (2007) 302-306
15. Nozoe T., Yasuda M., Honda M., et al. Clinicopathologic significance in serum presence of anti-p53 antibody in patients with colorectal carcinoma. Hepatogastroenterology 54 (2007) 1422-1425
16. Balogh G.A., Mailo D.A., Corte M.M., et al. Mutant p53 protein in serum could be used as a molecular marker in human breast cancer. Int J Oncol 28 (2006) 995-1002
17. Eto M., Kodama S., Uemura N., et al. Antibody responses to survivin and their clinical significance in patients with head and neck cancer. Head Neck 29 (2007) 1128-1135
18. Chow V., Yuen A.P., Lam K.Y., et al. Prognostic significance of serum p53 protein and p53 antibody in patients with surgical treatment for head and neck squamous cell carcinoma. Head Neck 23 (2001) 286-291
19. Saleh J., Brunner C., Gölzer R., et al. p53 autoantibodies from patients with head and neck cancer recognise common epitopes on the polypeptide chain of p53. Cancer Lett 233 (2006) 48-56
20. Smith E.M., Donghong W., Rubenstein L.M., et al. Association between p53 and Human Papillomavirus in Head and Neck Cancer Survival. Cancer Epidemiol Biomarkers Prev 17 (2008) 421-427